Gradient-dependent inhibition of stimulatory signaling from platelet G protein-coupled receptors

Abstract

As platelet activation is an irreversible and potentially harmful event, platelet stimulatory signaling must be tightly regulated to ensure the filtering-out of inconsequential fluctuations of agonist concentrations in the vascular milieu. Herein, we show that platelet activation via G protein-coupled receptors is gradient-dependent, i.e., determined not only by agonist concentrations per se but also by how rapidly concentrations change over time. We demonstrate that gradient-dependent inhibition is a common feature of all major platelet stimulatory G protein-coupled receptors, while platelet activation via the non-G protein-coupled receptor glycoprotein VI is strictly concentration-dependent. By systematically characterizing the effects of variations in temporal agonist concentration gradients on different aspects of platelet activation, we demonstrate that gradient-dependent inhibition of protease-activated receptors exhibits different kinetics, with platelet activation occurring at lower agonist gradients for protease-activated receptor 4 than for protease-activated receptor 1, but shares a characteristic bimodal effect distribution, as gradient-dependent inhibition increases over a narrow range of gradients, below which aggregation and granule secretion is effectively shut off. In contrast, the effects of gradient-dependent inhibition on platelet activation via adenosine diphosphate and thromboxane receptors increase incrementally over a large range of gradients. Furthermore, depending on the affected activation pathway, gradient-dependent inhibition results in different degrees of refractoriness to subsequent autologous agonist stimulation. Mechanistically, our study identifies an important role for the cyclic adenosine monophosphate-dependent pathway in gradient-dependent inhibition. Together, our findings suggest that gradient-dependent inhibition may represent a new general mechanism for hemostatic regulation in platelets.

Multidimensional flow cytometry reveals novel platelet subpopulations in response to prostacyclin

“…We found that PGI 2 failed to inhibit agonist‐induced CD62P despite reducing fibrinogen binding in the same platelets. In support of this observation, a recent study demonstrated agonist‐dependent platelet sensitivity to PGI 2 , where CD62P expression had far greater resistance to PGI 2 ‐mediated inhibition than fibrinogen‐mediated aggregation in paired samples that were stimulated with CRP‐XL 48 . Exploring this observation further with our new assay and analysis, we show for the first time that PGI 2 can reduce the generation of procoagulant subsets.…”

Long-term platelet priming after glycoprotein VI stimulation in comparison to Protease-Activating Receptor (PAR) stimulation

“…This points to a mechanism of thrombin receptor desensitisation after platelet exposure to PAR agonists [ 33 , 34 ]. It also underlines the idea that platelet exposure to a gradient of GPCR agonists causes response diminishment [ 35 ].…”

Effects of Heparin and Bivalirudin on Thrombin-Induced Platelet Activation: Differential Modulation of PAR Signaling Drives Divergent Prothrombotic Responses

“…Flow cytometry was performed on a Gallios™ flow cytometer (Beckman Coulter Inc., Fullerton, CA, US) as described earlier ( 20 , 21 ) with minor modifications. Washed platelets were incubated with inhibitors as described above.…”